412 filings
Page 9 of 21
CORRESP
kfpofzod54 adg
11 Feb 21
Correspondence with SEC
12:00am
UPLOAD
fxin6tvq
11 Feb 21
Letter from SEC
12:00am
424B3
qn81tolkk l5v1ax7yei
9 Feb 21
Prospectus supplement
5:06pm
8-K
bo8 vdljl
9 Feb 21
Termination of a Material Definitive Agreement
4:59pm
S-8
djr34cwl6nu09b8
4 Feb 21
Registration of securities for employees
5:27pm
D
eeyr0l fm9uab
4 Feb 21
$44.03M in options / securities to be acquired, sold $44.03M, 15 investors
4:18pm
424B3
ok8u8ey4kcj78n9dq mr
27 Jan 21
Prospectus supplement
9:22am
8-K
xeksd6y5ug2u5cd13u4
27 Jan 21
KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder
9:17am
424B3
zdnpm
26 Jan 21
Prospectus supplement
5:02pm
8-K
45ejx3irjv9infhwyw
26 Jan 21
Entry into a Material Definitive Agreement
9:16am
EFFECT
sij k1xw63g4951
25 Jan 21
Notice of effectiveness
12:19am
424B5
ndd jbnpbfeifo2o
22 Jan 21
Prospectus supplement for primary offering
5:24pm
CORRESP
mam6z wup
20 Jan 21
Correspondence with SEC
12:00am
UPLOAD
cmc6s86nmf33ceb dv
19 Jan 21
Letter from SEC
12:00am
D
tc2l 9lu9
13 Jan 21
$31.48M in equity / options / securities to be acquired, sold $31.48M, 4 investors
4:15pm
8-K
add7sd7e4h1ndqdz
13 Jan 21
KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
12:00am
424B4
876zxw qx9
8 Jan 21
Prospectus supplement with pricing info
9:38pm
EFFECT
j2681cxv ryjbd7n
8 Jan 21
Notice of effectiveness
12:15am